Lessons for dialysis investigators from the Steno-2 Study

Journal of Nephrology

Volumn 21, Issue 1, 2008, Pages 6-13

  McFarlane, Philip A ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Attributable risk; Clinical trial design; Dialysis; Kidney failure

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; SIMVASTATIN;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEART PROTECTION; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MINERAL METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL TIME; TREATMENT FAILURE; DIABETIC NEPHROPATHY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; UREMIA;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RESEARCH DESIGN; UREMIA;

EID: 43249128899     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-S119.
2. Canadian Organ Replacement Registry (CORR). 2001 annual report. Ottawa, ON: Canadian Institute for Health Information; 2001.
3. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35:S117-S131.
4. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
5. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
9. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
10. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13:1307-1320.
11. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. [see comment]. N Engl J Med. 2002;347:2010-2019.
12. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1041-1043.
13. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of the attributable risk of cancer due to cigarette smoking. Am J Public Health. 1992;82:37-40.
14. Rabe C, Lehnert-Batar A, Gefeller O. Generalized approaches to partitioning the attributable risk of interacting risk factors can remedy existing pitfalls. J Clin Epidemiol. 2007;60:461-468.
15. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health. 1998;88:15-19.
16. Rockhill B, Weinberg C. Error in population attributable risk calculation. Epidemiology. 1996;7:453-454.
17. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
18. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
19. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820-825.
20. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group [see comments]. Lancet. 1998;351:1755-1762.
21. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
22. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. (comment]. N Engl J Med. 2003;348:383-393.
23. Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet. 2005;365:1348-1353.
24. Bell CM, Chapman RH, Stone PW, et al. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making. 2001;21:288-294.
25. Herman J. Shortcomings of the randomized controlled trial: a view from the boondocks. J Eval Clin Pract. 1998;4:283-286.
26. Isbel NM, Haluska B, Johnson DW, et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J. 2006;151:745-753.
27. McFarlane PA, Bayoumi AM, Pierratos A, et al. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int. 2003;64:1004-1011.
28. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group [see comments]. JAMA. 1990;263:825-830.
29. Fox E, Peace K, Neale TJ, et al. Quality of life for patients with end-stage renal failure. Ren Fail. 1991;13:31-35.
30. Gudex CM. Health-related quality of life in endstage renal failure. Qual Life Res. 1995;4:359-366.